Re-(CO) 3 -A7 solution into tumor-bearing mice.
] + with A7 at 43ºC for 2 hours.
Introduction
Radioimmunotherapy with radiolabeled monoclonal antibodies (mAb) has great potential to be a good treatment modality for cancer patients. In particular, radioimmunotherapy in B-cell non-Hodgkin's lymphoma targeting the CD20 antigen, which is found on the B-cell surface, has clearly demonstrated its efficacy [1, 2] . Consequently, 90 Y ibritumomab tiuxetan (Zevalin) and 131 I tositumomab (Bexxar), both targeting the CD20 antigen, have been approved by the United States Food and Drug Administration for treatment of refractory or relapsed low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma [3, 4] . Both radiopharmaceuticals have been shown to produce high response rates, but they also have some shortcomings as radionuclides. 131 I emits a high energy gamma ray, 364 keV, that is not ideal for imaging and exposes patients to unnecessary radiation. Meanwhile, because 90 Y is a pure beta emitter, imaging is difficult with 90 Y-mAb and dosimetry should be performed with 111 In-mAb before the 90 Y-mAb therapy. However,
111
In-mAb might not accurately predict the dosimetry of 90 Y-mAb because it has been reported that 111 In-mAb did not parallel the uptake of 86 Y-mAb in bone [5] .
Rhenium has two useful radionuclides for radionuclide therapy, 186 Re and 188 Re. 186 Re and 188 Re are currently considered to be appropriate candidates for therapeutic applications due to their favorable nuclear properties [6, 7] . Both rhenium radioisotopes decay with the emission of not only beta particles for therapy but also gamma rays, which are suitable for Buckinghamshire, England) with saline as the eluate.
In Vitro Stability
Ogawa et al. Page 10/29 To evaluate its stability, 188 Re-(CO) 3 -A7 in saline solution was incubated at 37˚C. After incubation for 24 hours, a sample was drawn and its radioactivity was analyzed by CAE and TLC. In addition, 188 Re-(CO) 3 -A7 solutions were diluted 10-fold with a 0.1 M solution of histidine or freshly prepared murine plasma, and the solutions were incubated at 37˚C. After 1, 3, and 24 hours incubation, the radioactivity of each sample was analyzed by TLC.
Biodistribution in tumor-bearing mice
Experiments with animals were conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals of Kanazawa University. The animals were housed with free access to food and water at 23°C with a 12-hour alternating light/dark schedule. LS180 human colon carcinoma cells were obtained from ATCC (Manassas, VA) and grown in cell culture dishes in Eagle's minimum essential medium with phenol red, 10% heat-inactivated fetal calf serum, 100 μg/mL glutamine, 100 units/mL penicillin, and 100 μg/mL streptomycin. The cells were cultured in a humidified atmosphere of 95% air and 5% carbon dioxide at 37°C. They
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Next, to produce tumors, the mice to be inoculated were anesthetized with pentobarbital and approximately 5 × 10 6 cells were injected subcutaneously into the right shoulder of 4-week-old BALB/c nu/nu female mice (15-19 g ).
Biodistribution experiments were performed approximately 8 days postinoculation, i.e., the time required for the tumors to reach a palpable size. Groups of four or five mice were administered 100 μL 186 Re-(CO) 3 -A7, 188 Re-(CO) 3 -A7, or 125 I-A7 (7.4 kBq, A7:100 μg, respectively) intravenously and sacrificed at 1 and 24 hours postinjection.
Tissues of interest were removed and weighed, and radioactivity counts were determined with an Auto Well Gamma System (ARC-380; Aloka, Tokyo, Japan) and corrected for background radiation and physical decay during counting.
Results

Preparation of 186/188
Re-(CO) 3 -A7 [20] . In CAE analyses, intact A7 migrated to the 2-2.5 cm anode from the origin, which was determined by Ponceau S dye, and 186/188 Re-(CO) 3 -A7 also migrated to the 2-2.5 cm anode (Figure 1) showed a radiochemical purity of over 95%.
In Vitro Stability
After incubation in saline for 24 hours, about 93% of the 188 Re-(CO) 3 -A7 remained intact. In murine plasma, over 90% of radioactivity existed in a protein fraction for 24 hours, indicating that the 188 Re-(CO) 3 -A7 is not degraded to 188 ReO 4 -in plasma. When challenged with an excess of histidine, part of the radioactivity dissociated from 188 Re-(CO) 3 -A7 (Figure 2 ).
Biodistribution in tumor-bearing mice
The biodistributions of 186 Re-(CO) 3 -A7, 188 Re-(CO) 3 -A7, and 125 I-A7 in tumor-bearing mice are listed in Tables 1-3 . As we expected, both radiorhenium-labeled A7 had almost identical biodistribution. 186 Re-(CO) 3 In other previous studies, it was reported that a radioiodine-labeled antibody, 88 Y-isothiocyanatobenzyl-DTPA-antibody, and 186 Re-MAG3-antibody showed similar blood clearances [25, 26] . However, in this study, the radioactivity (%dose/g) in blood at 24 hr postinjection of 186 Re-(CO) 3 -A7, 188 Re-(CO) 3 -A7, and 125 I-A7 were 6.2 ±0.3, 5.9 ±0.8, and Re-(CO) 3 -A7 in this study, these results are also not inconsistent with our hypothesis.
Faster blood clearance is advantageous for fewer side effects because myelosuppression is the chief side effect associated with radioimmunotherapy [28] . However, faster blood clearance compromises Re-labeled antibodies.
Conclusion
186/188
Re-labeled A7 showed high uptakes in tumors the same as that of 125 I labeled A7. However, further modifications of the labeling method would be necessary in order to improve radiochemical yields and their biodistribution. 
